

BREAKDOWN OF CHILDHOOD VACCINE INSERTS' PRE-LICENSING STUDIES

	VACCINE/Breakdown Tables Groups Compared	VACCINE MANUFACTURER & BRAND NAME	# In Study	Monitor Period	Saline Placebo Group	Cancer Study	Fertility Study
	Hepatitis B / None -- In two sets of studies, there were only vaccinated children. In a third set they compared those that received three doses with a group that received two doses	Merck: Recombivax HB	147 1,252 Unk.	5 d	No	No	No
	Diphtheria, tetanus, acellular pertussis (DTaP or Tdap) / Yes -- Three studies in US, 4,198: participants were enrolled to receive four consecutive doses of Pentacel. Fourth study in Canada, 1,782 participants previously vaccinated with three doses of Pentacel received a fourth dose. Compared vaccine with other vaccines	(a) Sanofi Pasteur: Pentacel	5,980 1,782	3 d	No	No	No
	Diphtheria, tetanus, acellular pertussis (DTaP or Tdap) / Yes -- Compares Daptacel vaccine to DT and DTP	(b) Sanofi Pasteur: DAPTACEL	8,197	14 d 2 months	No	No	No
	Diphtheria, tetanus, acellular pertussis (DTaP or Tdap) /Yes -- Compared Adacel to DECAVAC (Tetanus and Diphtheria Toxoids Adsorbed; manufactured by Sanofi Pasteur Inc., Swiftwater, PA)	(c) Sanofi Pasteur: Adacel	7,143	14 d 6 months	No	No	No
	Haemophilus influenzae type b (Hib) / Yes -- Compares groups that received 1, 2 and 3 doses of DAPTACEL + IPOL + ActHIB Vaccines with a group that received DAPTACEL + ActHIB Vaccines	Sanofi Pasteur: ActHIB	110 1,454	48 hrs. 3 d 30 d	No	No	No
	Pneumococcal conjugate or polysaccharide / Tables -- Compares Prevnar 13 with Prevnar	Pfizer: Prevnar 13	7,489	4 d 7 d	No	No	No
	Inactivated poliovirus (IPV) / Yes -- Compares IPV only schedules and sequential IPV-OPV schedules; compares IPOL with IPOL + DTP	Sanofi Pasteur: IPOL	+700 + 3,000 (exact number not reported)	18 Months	No	No	No

BREAKDOWN OF CHILDHOOD VACCINE INSERTS' PRE-LICENSING STUDIES

	VACCINE/Breakdown Tables Groups Compared	VACCINE MANUFACTURER & BRAND NAME	# In Study	Monitor Period	Saline Placebo Group	Cancer Study	Fertility Study
	Measles-mumps-rubella (MMR) / No -- No pre-license studies reported	Merck: M-M-R II	Unk.	Unk.	No	No	No
	Varicella (chickenpox) / Yes -- Says no placebo-controlled group in current vaccine. Mentions placebo-controlled group, but the placebo contained 45 mg of neomycin, an antibiotic with serious side effects	Merck: Varivax	11,000 914	42 d	No	No	No
	Meningococcal conjugate or polysaccharide / Yes -- Compares Menactra vaccine to Menactra + PCV7a + MMRVb + HepA, and PCV7a + MMRVb + HepA	Sanofi Pasteur: Menactra	3,721	7 d	No	No	No
	Hepatitis A / Yes -- Compares VAQTA vaccine to VAQTA + ProQuad + Prevnar concomitantly - Only solicited reactions	Merck: VAQTA	+10,000 (exact number not reported)	14 d 5 d	No	No	No
	Rotavirus / Yes -- Mentions Placebo group, but the Placebo contained Polysorbate 80 and many other substances -- In 42 day period 52 deaths reported	Merck: RotaTeg	71,725	42 d	No	No	No
	Human Papillomavirus (HPV) / Yes -- Compares Gardasil group to AAHS and Saline Placebo groups, but reports AAHS and Saline Placebo groups as one unit -- The Saline Placebo group (594) had zero Systemic Autoimmune Disorders reported. See Plotkin Deposition transcript, pages 197 to 202, at https://tinyurl.com/Plotkin-Deposition-Transcript ; see also Deposition video at https://tinyurl.com/HPV-Placebo-Study	Merck: Gardasil	18,083 Placebo Group = 594 (3.29% of total)	14 d	Yes	No	No